This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $96.43 in the latest trading session, marking a +0.08% move from the prior day.
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies
Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.
The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev
Top Stock Reports for Alphabet, Merck & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).
Medtronic's LINQ II ICM Gets Multiple Regulatory Approvals
by Zacks Equity Research
Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.
Medtronic Launches User-Friendly Insulin Infusion Set in US
by Zacks Equity Research
Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.
Medical Products Industry's Near-Term Outlook Lacks Spark
by Trina Mukherjee
AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $92.32, marking a +0.68% move from the previous day.
Medtronic's DBS System With BrainSense Technology Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.
Remote Patient Monitoring Gains Prominence: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are committed toward enhancing and offering RPM to fight against coronavirus.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $88.86, moving -0.08% from the previous trading session.
Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks
by Sriparna Ghosal
In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.
Medtronic's Evolut TAVI Gets CE Mark for Low-Risk Patients
by Zacks Equity Research
Medtronic's (MDT) Evolut system shows a lower rate of the composite of all-cause death or disabling stroke with TAVI at 30 days.
Medtronic (MDT) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic Partners Foxconn to Scale Up Ventilator Production
by Zacks Equity Research
Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.
Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block
by Zacks Equity Research
With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.
3 MedTech Stocks to Watch Amid Coronavirus Catastrophe
by Trina Mukherjee
Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.
Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management
by Zacks Equity Research
Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
The Smart Future: Will Robotics Call the Shots Post Coronavirus?
by Zacks Equity Research
Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.
Medtronic's StealthStation Feature Recall Classified Class I
by Zacks Equity Research
This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.
Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy
by Zacks Equity Research
Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.